MCID: SFT003
MIFTS: 56

Soft Tissue Sarcoma

Categories: Rare diseases, Cancer diseases

Aliases & Classifications for Soft Tissue Sarcoma

MalaCards integrated aliases for Soft Tissue Sarcoma:

Name: Soft Tissue Sarcoma 50 29 41
Sarcoma 69

Classifications:



Summaries for Soft Tissue Sarcoma

NIH Rare Diseases : 50 soft tissuesarcoma is a form of cancer that occurs due to abnormal and uncontrolled cell growth of the "soft tissues" of the body. these tissues connect, support and surround other body parts and may include muscle, fat, blood vessels, lymph vessels, nerves, tendons and the lining of joints. many people with early soft tissue sarcoma have no signs or symptoms of the condition. when present, symptoms depend on the location and size of the tumor but may include a palpable lump under the skin, pain, or difficulty breathing. most cases occur sporadically in people with little to no family history of the condition. people who have previously received radiation therapy and those with certain inherited disorders (such as gorlin syndrome, gardner syndrome, li-fraumeni syndrome, tuberous sclerosis, neurofibromatosis type 1, and werner syndrome) have an increased risk of developing a soft tissue sarcoma. the best treatment options depend on many factors but may include surgery, chemotherapy, and radiation therapy. last updated: 10/17/2016

MalaCards based summary : Soft Tissue Sarcoma, also known as sarcoma, is related to gastrointestinal stromal tumor and liposarcoma. An important gene associated with Soft Tissue Sarcoma is MDM2 (MDM2 Proto-Oncogene), and among its related pathways/superpathways are PEDF Induced Signaling and TGF-Beta Pathway. The drugs Cyclophosphamide and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and t cells, and related phenotypes are Increased cell death HMECs cells and endocrine/exocrine gland

MedlinePlus : 41 your soft tissues connect, support, or surround other tissues. examples include your muscles, tendons, fat, and blood vessels. soft tissue sarcoma is a cancer of these soft tissues. there are many kinds, based on the type of tissue they started in. they may cause a lump or swelling in the soft tissue. sometimes they spread and can press on nerves and organs, causing problems such as pain or trouble breathing. no one knows exactly what causes these cancers. they are not common, but you have a higher risk if you have been exposed to certain chemicals, have had radiation therapy, or have certain genetic diseases. doctors diagnose soft tissue sarcomas with a biopsy. treatments include surgery to remove the tumor, radiation therapy, chemotherapy, or a combination. nih: national cancer institute

Wikipedia : 72 A soft-tissue sarcoma is a form of sarcoma that develops in connective tissue, though the term is... more...

Related Diseases for Soft Tissue Sarcoma

Diseases related to Soft Tissue Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 211)
id Related Disease Score Top Affiliating Genes
1 gastrointestinal stromal tumor 31.4 EGFR MKI67 TP53 VEGFA
2 liposarcoma 31.1 EWSR1 MDM2
3 spindle cell sarcoma 30.2 EWSR1 MDM2 TP53
4 lung cancer 26.2 ABCB1 BCL2 EGFR MDM2 TERT TP53
5 colorectal cancer 24.8 ABCB1 BCL2 EGFR IFNG MDM2 MKI67
6 soft tissue sarcoma childhood 12.1
7 alveolar soft-part sarcoma 11.8
8 dermatofibrosarcoma protuberans 11.4
9 epithelioid sarcoma 11.3
10 rhabdomyosarcoma 11.3
11 embryonal rhabdomyosarcoma 11.2
12 myxoid liposarcoma 11.2
13 li-fraumeni syndrome 11.2
14 sarcoma, synovial 11.1
15 sarcoma 11.1
16 hemangiopericytoma, malignant 11.0
17 undifferentiated pleomorphic sarcoma 11.0
18 rhabdomyosarcoma 2, alveolar 10.8
19 rhabdomyosarcoma, somatic 10.8
20 rhabdomyosarcoma, embryonal, 2 10.8
21 muscle cancer 10.8
22 heart malignant hemangiopericytoma 10.8
23 follicular dendritic cell sarcoma 10.8
24 connective tissue disease 10.8
25 rnase t2-deficient leukoencephalopathy 10.8 MDM2 TP53
26 thai symphalangism syndrome 10.7 LATS1 TP53
27 split hand split foot nystagmus 10.6 MKI67 TP53
28 rectum squamous cell carcinoma 10.6 MDM2 TP53
29 vulvar liposarcoma 10.6 MDM2 TP53
30 lichen nitidus 10.6 MDM2 TP53
31 epidural neoplasm 10.6 MDM2 VEGFA
32 sternal cleft 10.6 IFNG TNF
33 autoimmune polyglandular syndrome type 3 10.6 IFNG TNF
34 cutaneous leishmaniasis 10.5 TNF VEGFA
35 mosaic trisomy 1 10.5 IFNG TNF
36 acute cholinergic dysautonomia 10.5 MDM2 TNF TP53
37 lung clear cell-sugar-tumor 10.5 EWSR1 MDM2 TP53
38 mediastinum rhabdomyosarcoma 10.5 EWSR1 MDM2 TP53
39 vitamin d-dependent rickets, type i 10.5 EWSR1 MDM2 TP53
40 primary systemic mycosis 10.5 IFNG TNF
41 pulmonary hypertension 10.5 BCL2 TNF
42 accessory nerve disease 10.5 EWSR1 MDM2 TP53
43 enamel hypoplasia cataract hydrocephaly 10.5 MDM2 MKI67 TP53
44 limb-body wall complex 10.4 TNF TP53
45 hypogonadotropic hypogonadism-retinitis pigmentosa syndrome 10.4 EGFR TP53
46 ovarian mesodermal adenosarcoma 10.4 BCL2 TP53
47 acute vascular insufficiency of intestine 10.4 IFNG TNF TP53
48 endometrial clear cell adenocarcinoma 10.3 IFNG TNF TP53
49 central sleep apnea 10.3 IFNG TNF TP53
50 childhood infratentorial neoplasm 10.3 EGFR TP53

Graphical network of the top 20 diseases related to Soft Tissue Sarcoma:



Diseases related to Soft Tissue Sarcoma

Symptoms & Phenotypes for Soft Tissue Sarcoma

GenomeRNAi Phenotypes related to Soft Tissue Sarcoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death HMECs cells GR00103-A-0 9.02 EGFR EWSR1 IL3 MDM2 TP53

MGI Mouse Phenotypes related to Soft Tissue Sarcoma:

44 (show all 21)
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.27 BCL2 IFNG ABCB1 EGFR TERT MDM2
2 growth/size/body region MP:0005378 10.26 BCL2 ABCB1 EGFR LATS1 IFNG MDM2
3 cardiovascular system MP:0005385 10.25 BCL2 ABCB1 EGFR IFNG MDM2 LATS1
4 cellular MP:0005384 10.24 EGFR BCL2 LATS1 IFNG MDM2 TERT
5 homeostasis/metabolism MP:0005376 10.24 EGFR BCL2 ABCB1 LATS1 IFNG MDM2
6 digestive/alimentary MP:0005381 10.23 IFNG ABCB1 EGFR BCL2 MDM2 TERT
7 hematopoietic system MP:0005397 10.2 BCL2 ABCB1 EGFR IFNG MDM2 TERT
8 immune system MP:0005387 10.18 EGFR BCL2 ABCB1 IFNG MDM2 TERT
9 mortality/aging MP:0010768 10.18 EGFR BCL2 ABCB1 LATS1 IFNG MDM2
10 craniofacial MP:0005382 10.13 BCL2 EGFR IFNG MDM2 VEGFA TP53
11 integument MP:0010771 10.11 BCL2 EGFR IFNG MDM2 LATS1 VEGFA
12 liver/biliary system MP:0005370 10.1 IFNG ABCB1 EGFR MDM2 LATS1 TP53
13 nervous system MP:0003631 10.1 BCL2 ABCB1 EGFR TERT IFNG MDM2
14 neoplasm MP:0002006 10.09 IFNG EGFR BCL2 MDM2 LATS1 TERT
15 muscle MP:0005369 10 BCL2 EGFR IFNG MDM2 TP53 TNF
16 no phenotypic analysis MP:0003012 9.97 IFNG ABCB1 EGFR MDM2 LATS1 TP53
17 normal MP:0002873 9.92 EGFR TERT IFNG MDM2 MKI67 LATS1
18 reproductive system MP:0005389 9.85 IFNG ABCB1 EGFR BCL2 MDM2 LATS1
19 renal/urinary system MP:0005367 9.73 EGFR BCL2 IFNG MDM2 TP53 VEGFA
20 respiratory system MP:0005388 9.5 BCL2 EGFR TERT IFNG TP53 TNF
21 skeleton MP:0005390 9.17 EGFR IFNG MDM2 TNF TERT TP53

Drugs & Therapeutics for Soft Tissue Sarcoma

Drugs for Soft Tissue Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 592)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
2
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
3
Bleomycin Approved Phase 4,Phase 3,Phase 2,Phase 1 11056-06-7 5360373
4
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
5
Efavirenz Approved, Investigational Phase 4,Phase 3 154598-52-4 64139
6
Ritonavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 155213-67-5 392622
7
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
8
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 43805 6857599
9
Lamivudine Approved, Investigational Phase 4,Phase 2,Phase 3 134678-17-4 60825
10
Nevirapine Approved Phase 4,Phase 3 129618-40-2 4463
11
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
12
Emtricitabine Approved, Investigational Phase 4,Phase 3 143491-57-0 60877
13
Lopinavir Approved Phase 4,Phase 2,Phase 3 192725-17-0 92727
14
Capecitabine Approved, Investigational Phase 4,Phase 2,Phase 1 154361-50-9 60953
15
Aspirin Approved, Vet_approved Phase 4,Phase 2 50-78-2 2244
16
Dalteparin Approved Phase 4,Phase 1 9005-49-6
17
Heparin Approved, Investigational Phase 4,Phase 1 9005-49-6 772 46507594
18
Ethiodized oil Approved Phase 4 8008-53-5
19
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
20 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
21 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
22 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
23 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
25 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
26 Vaccines Phase 4,Phase 1,Phase 2
27 Anti-HIV Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
28 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1
30 Anti-Retroviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
31 Antiviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
32 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
33 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
34
protease inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
35 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Antimetabolites, Antineoplastic Phase 4,Phase 2,Phase 3,Phase 1
38 Antibodies Phase 4,Phase 3,Phase 1,Phase 2
39 Antibodies, Monoclonal Phase 4,Phase 3,Phase 1,Phase 2
40 Immunoglobulins Phase 4,Phase 3,Phase 1,Phase 2
41 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
42 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
43 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
44 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1
45 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
46 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
47 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 3,Phase 2,Phase 1
48 Reverse Transcriptase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
49 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3
50 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 2,Phase 3

Interventional clinical trials:

(show top 50) (show all 1647)

id Name Status NCT ID Phase Drugs
1 EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children Unknown status NCT00339118 Phase 4 doxorubicin, cytoxan
2 Optimizing Influenza Vaccination in Surgical Oncology Patients Unknown status NCT01698177 Phase 4
3 HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXT Completed NCT00380770 Phase 4 Generic HAART Triomune : d4T, 3TC, NVP;Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV
4 Anti-Retrovirals for Kaposi's Sarcoma Completed NCT00444379 Phase 4 Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir
5 OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum. Completed NCT00577031 Phase 4 bevacizumab [Avastin];Oxaliplatin;Xeloda
6 Physical Characteristics of Retrieved Massive Allografts Completed NCT00160758 Phase 4
7 HLA Sensitization Following Major Cortical Allograft Bone Procedures Completed NCT00160719 Phase 4
8 Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer Recruiting NCT02301962 Phase 4 Panitumumab
9 Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma Recruiting NCT01669369 Phase 4 Lithium Carbonate;Placebo
10 Stereotactic Body Radiotherapy for Head and Neck Tumors Active, not recruiting NCT01344356 Phase 4
11 Evaluation of Hyperbaric Oxygen Therapy on Wound Healing Following Management of Soft Tissue Sarcoma With Neo-Adjuvant Radiation and Surgical Resection Not yet recruiting NCT03144206 Phase 4 Hyperbaric oxygen
12 Low Molecular Weight Heparin (LMWH) vs Aspirin for Venous Thromboembolism (VTE) Prophylaxis in Orthopaedic Oncology Not yet recruiting NCT03244020 Phase 4 Aspirin 325mg;Enoxaparin 40Mg/0.4mL Prefilled Syringe
13 Evaluation of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization. Not yet recruiting NCT02625389 Phase 4 Lipiodol® Ultra Fluid with surgical glues
14 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
15 An Adequate Cost Effective Follow Up Protocol For Bone & Soft Tissue Sarcomas - A Prospective Randomized Trial Unknown status NCT00384735 Phase 3
16 The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas Unknown status NCT00162721 Phase 3 doxorubicin, ifosfamide, cisplatin
17 Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma Unknown status NCT00002516 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;mesna;vincristine sulfate
18 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Unknown status NCT00020566 Phase 3 busulfan;doxorubicin hydrochloride;etoposide;ifosfamide;melphalan;vincristine sulfate
19 A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma Unknown status NCT00002318 Phase 3 Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride
20 Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma Unknown status NCT00379457 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate;vinorelbine tartrate
21 TB-IRIS NSAID Cox-2 Inhibitor Prevention Trial Unknown status NCT02060006 Phase 3 Meloxicam 7.5mg daily for 8 weeks
22 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
23 Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumor Unknown status NCT00685828 Phase 3 imatinib mesylate
24 Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor Unknown status NCT00103168 Phase 3 imatinib mesylate
25 A Clinical Trial on Efficacy and Safety for Lobaplatin and Gemcitabine in Combination With Docetaxel in the Second-line Treatments on Advanced Osteosarcoma Unknown status NCT02099396 Phase 2, Phase 3 Docetaxel+lobaplatin;Gemcitabine+lobaplatin
26 Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma Unknown status NCT00691236 Phase 2, Phase 3 Zoledronic acid;Standard chemotherapy
27 A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma Completed NCT01440088 Phase 3 TH-302 in Combination with Doxorubicin;Doxorubicin
28 Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma Completed NCT00142571 Phase 3 Gemcitabine;Docetaxel
29 Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy Completed NCT00753688 Phase 3 PAZOPANIB;Placebo
30 Phase 3 Study to Treat Patients With Soft Tissue Sarcomas Completed NCT02049905 Phase 3 Aldoxorubicin;Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)
31 Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma Completed NCT01168791 Phase 3 doxorubicin in combination with palifosfamide-tris;doxorubicin in combination with placebo
32 Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma Completed NCT01327885 Phase 3 Eribulin mesylate 1.4 mg/m^2 intravenous;Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV
33 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
34 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
35 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
36 A Prospective Randomized Trial of Pre-Operative IMRT+Surgery Versus Surgery Alone For Primary Retroperitoneal Sarcoma Completed NCT00131898 Phase 3
37 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
38 A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue Sarcoma Completed NCT00001300 Phase 3 doxorubicin;ifosfamide;mesna
39 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
40 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
41 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
42 Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor Completed NCT00006734 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
43 A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies Completed NCT00699517 Phase 3 OMBRABULIN (AVE8062);Placebo
44 Doxorubicin in Treating Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00002985 Phase 3 daunorubicin hydrochloride;pegylated liposomal doxorubicin hydrochloride
45 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
46 Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6) Completed NCT00538239 Phase 3 ridaforolimus;Placebo
47 An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS) Completed NCT00796120 Phase 3 Trabectedin;Doxorubicin;Ifosfamide
48 A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma Completed NCT00002319 Phase 3 Doxorubicin hydrochloride (liposomal)
49 Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma. Completed NCT00002147 Phase 3 Doxorubicin hydrochloride (liposomal)
50 Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma Completed NCT00003350 Phase 3 paclitaxel;pegylated liposomal doxorubicin hydrochloride

Search NIH Clinical Center for Soft Tissue Sarcoma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Soft Tissue Sarcoma

Genetic tests related to Soft Tissue Sarcoma:

id Genetic test Affiliating Genes
1 Soft Tissue Sarcoma 29

Anatomical Context for Soft Tissue Sarcoma

MalaCards organs/tissues related to Soft Tissue Sarcoma:

39
Bone, Lung, T Cells, Uterus, Brain, Kidney, Testes

Publications for Soft Tissue Sarcoma

Articles related to Soft Tissue Sarcoma:

(show top 50) (show all 1017)
id Title Authors Year
1
The importance of treating by histological subtype in advanced soft tissue sarcoma. ( 27918201 )
2017
2
Appendix 3: Soft tissue sarcoma: MCBS eUpdate published online 5 May 2017(www.esmo.org/Guidelines/Sarcoma-and-GIST). ( 28881924 )
2017
3
Curcumin and Viscum album Extract Decrease Proliferation and Cell Viability of Soft-Tissue Sarcoma Cells: An In Vitro Analysis of Eight Cell Lines Using Real-Time Monitoring and Colorimetric Assays. ( 28045549 )
2017
4
Myositis ossificans in elbow mimicking soft tissue sarcoma: Similar clinical and radiological findings. ( 28641932 )
2017
5
Olaratumab for the treatment of advanced soft tissue sarcoma. ( 28862476 )
2017
6
GeDDiS: insight into frontline therapy in soft tissue sarcoma. ( 28882535 )
2017
7
Optimal post-operative radiation after soft-tissue sarcoma resection is achieved in less than two thirds of cases. ( 28842782 )
2017
8
Salvage Therapy in Advanced Adult Soft Tissue Sarcoma: A Systematic Review and Meta-Analysis of Randomized Trials. ( 28835514 )
2017
9
Surgical considerations when reporting MRI studies of soft tissue sarcoma of the limbs. ( 28884363 )
2017
10
Cost-Effectiveness Analysis of Preoperative Versus Postoperative Radiation Therapy in Extremity Soft Tissue Sarcoma. ( 28068242 )
2017
11
Dramatic Reduction in Tumor Size During 5 Months of Pazopanib Therapy in Combination With Ifosfamide, Carboplatin, and Etoposide in an Early Infant With Progressive Soft Tissue Sarcoma. ( 28067691 )
2017
12
Evolution in soft tissue sarcoma. ( 27918200 )
2017
13
PD-L1 Expression Is Associated with FOXP3+ Regulatory T-Cell Infiltration of Soft Tissue Sarcoma and Poor Patient Prognosis. ( 28819402 )
2017
14
Comparison of novel multi-level Otsu (MO-PET) and conventional PET segmentation methods for measuring FDG metabolic tumor volume in patients with soft tissue sarcoma. ( 28921170 )
2017
15
The fate of new fosfamides in phase III studies in advanced soft tissue sarcoma. ( 28841543 )
2017
16
External Beam Radiation Therapy for Resectable Soft Tissue Sarcoma: A Systematic Review and Meta-Analysis. ( 28895107 )
2017
17
Randomized Controlled Trials in Soft Tissue Sarcoma: We Are Getting There! ( 28923218 )
2017
18
Prediction of muscle strength and postoperative function after knee flexor muscle resection for soft tissue sarcoma of the lower limbs. ( 28827055 )
2017
19
Pitfalls in soft tissue sarcoma imaging: chronic expanding hematomas. ( 28887645 )
2017
20
Antia89proliferative activity of epigallocatechina893a89gallate and silibinin on soft tissue sarcoma cells. ( 27909727 )
2017
21
Treatment of soft tissue sarcoma: a focus on earlier stages. ( 27918202 )
2017
22
Benefit of Adjuvant Radiotherapy for Local Control, Distant Metastasis, and Survival Outcomes in Patients with Localized Soft Tissue Sarcoma: Comparative Effectiveness Analysis of an Observational Cohort Study. ( 28895087 )
2017
23
45 Gy is not sufficient radiotherapy dose for Group III orbital embryonal rhabdomyosarcoma after less than complete response to 12 weeks of ARST0331 chemotherapy: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. ( 28548706 )
2017
24
Surveillance Imaging Patterns and Outcomes Following Radiation Therapy and Radical Resection for Localized Extremity and Trunk Soft Tissue Sarcoma. ( 28058559 )
2017
25
MicroRNAs in Different Histologies of Soft Tissue Sarcoma: A Comprehensive Review. ( 28895916 )
2017
26
Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal. ( 28914440 )
2017
27
A noninterventional, multicenter, prospective phase IV study of trabectedin in patients with advanced soft tissue sarcoma. ( 28926423 )
2017
28
Aldoxorubicin for the treatment of soft tissue sarcoma. ( 28846045 )
2017
29
Extremity Soft Tissue Sarcoma: Tailoring Resection to Histologic Subtype. ( 27591492 )
2016
30
PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma. ( 27621408 )
2016
31
A pilot trial of doxorubicin containing phosphatidyldiglycerol based thermosensitive liposomes in spontaneous feline soft tissue sarcoma. ( 27592502 )
2016
32
The width of resection margins influences local recurrence in soft tissue sarcoma patients. ( 27107792 )
2016
33
SU-G-JeP4-14: Assessment of Inter- and Intra-Fractional Motion for Extremity Soft Tissue Sarcoma Patients by Using In-House Real-Time Optical Image-Based Monitoring System. ( 28047555 )
2016
34
Older Age Modifies Oncologic Outcome Following Radiotherapy in Soft-tissue Sarcoma: A Subtype-specific SEER Analysis. ( 27069154 )
2016
35
Prospective evaluation of Ki-67 system in histological grading of soft tissue sarcomas in the Japan Clinical Oncology Group Study JCOG0304. ( 27091124 )
2016
36
Outcome of extracranial malignant rhabdoid tumours in children registered in the European Paediatric Soft Tissue Sarcoma Study Group Non-Rhabdomyosarcoma Soft Tissue Sarcoma 2005 Study-EpSSG NRSTS 2005. ( 27082136 )
2016
37
GATA3 Expression Is a Poor Prognostic Factor in Soft Tissue Sarcomas. ( 27249072 )
2016
38
Chondroitin sulfate synthase 1 expression is associated with malignant potential of soft tissue sarcomas with myxoid substance. ( 26997434 )
2016
39
Individual and Combined Expression of DNA Damage Response Molecules PARP1, I^H2AX, BRCA1, and BRCA2 Predict Shorter Survival of Soft Tissue Sarcoma Patients. ( 27643881 )
2016
40
Time interval between surgery and start of adjuvant radiotherapy in patients with soft tissue sarcoma: A retrospective analysis of 1131 cases from the French Sarcoma Group. ( 27207359 )
2016
41
Potential pitfalls of mass spectrometry to uncover mutations in childhood soft tissue sarcoma: A report from the Children's Oncology Group. ( 27642091 )
2016
42
Evaluation of Soft Tissue Sarcoma Response to Preoperative Chemoradiotherapy Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging. ( 28066805 )
2016
43
(P035) The Prognostic Value of Pretreatment Peripheral Blood Neutrophil-to-Lymphocyte Ratio in Patients With Soft Tissue Sarcoma. ( 27083628 )
2016
44
Implications of staged reconstruction and adjuvant brachytherapy in the treatment of recurrent soft tissue sarcoma. ( 27180128 )
2016
45
Evaluation of minimal disseminated disease in cryopreserved ovarian tissue from bone and soft tissue sarcoma patients. ( 27591237 )
2016
46
Conservative strategy in infantile fibrosarcoma is possible: The European paediatric Soft tissue sarcoma Study GroupA experience. ( 26849118 )
2016
47
Extended resection including adjacent organs and Ki-67 labeling index are prognostic factors in patients with retroperitoneal soft tissue sarcomas. ( 26911364 )
2016
48
Association of the germline BRCA2 missense variation Glu2663Lys with high sensitivity to trabectedin-based treatment in soft tissue sarcoma. ( 27561088 )
2016
49
Symptom burden in advanced Soft Tissue Sarcoma. ( 28042077 )
2016
50
Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapy. ( 27208537 )
2016

Variations for Soft Tissue Sarcoma

Cosmic variations for Soft Tissue Sarcoma:

9
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM575 NRAS soft tissue,skin,sarcoma,NS c.38G>C p.G13A 12

Expression for Soft Tissue Sarcoma

Search GEO for disease gene expression data for Soft Tissue Sarcoma.

Pathways for Soft Tissue Sarcoma

Pathways related to Soft Tissue Sarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.59 BCL2 EGFR IFNG IL3 TNF TP53
2
Show member pathways
13.47 BCL2 EGFR IFNG IL3 TNF TP53
3
Show member pathways
13.35 BCL2 EGFR IL3 MDM2 TNF TP53
4
Show member pathways
13.25 BCL2 EGFR IFNG IL3 TNF TP53
5
Show member pathways
12.78 ABCB1 IFNG IL3 TNF VEGFA
6
Show member pathways
12.75 BCL2 IL3 MDM2 TNF TP53
7
Show member pathways
12.61 EGFR IFNG TNF TP53
8 12.58 BCL2 EGFR MDM2 TP53 VEGFA
9
Show member pathways
12.5 BCL2 EGFR IFNG TNF TP53
10
Show member pathways
12.47 BCL2 EGFR IL3 MDM2 TP53 VEGFA
11 12.45 LATS1 MDM2 MKI67 TP53
12
Show member pathways
12.39 BCL2 EGFR MDM2 TP53
13 12.24 BCL2 IFNG MDM2 TP53
14 12.21 ABCB1 BCL2 EGFR MDM2 TP53 VEGFA
15
Show member pathways
12.19 BCL2 EGFR MDM2 TP53
16 12.18 EWSR1 IL3 MDM2 TP53
17 12.14 EGFR MDM2 TNF TP53 VEGFA
18
Show member pathways
12.1 IFNG IL3 TNF
19 12.09 BCL2 EGFR IL3 MDM2 TERT TNF
20 12.02 IL3 TERT VEGFA
21 12.02 BCL2 MDM2 TP53
22 12.02 EGFR IFNG TNF TP53 VEGFA
23 12.01 EGFR TNF TP53
24 11.98 BCL2 MDM2 TP53 VEGFA
25 11.97 BCL2 EGFR MDM2 TP53
26 11.96 BCL2 TNF TP53
27 11.95 IFNG IL3 TNF
28 11.95 BCL2 EGFR MDM2 TP53 VEGFA
29 11.94 BCL2 MDM2 TP53
30
Show member pathways
11.93 BCL2 TNF TP53
31 11.92 EGFR MDM2 TP53
32 11.9 EGFR IFNG TNF TP53
33 11.87 BCL2 TNF TP53 VEGFA
34 11.86 BCL2 TNF VEGFA
35 11.86 BCL2 IFNG TNF TP53 VEGFA
36 11.85 EGFR IFNG IL3
37 11.82 IFNG TNF VEGFA
38 11.77 BCL2 EGFR IFNG VEGFA
39 11.76 IFNG MDM2 TP53
40
Show member pathways
11.72 IFNG IL3 TNF
41 11.7 BCL2 MDM2 TP53
42 11.65 EGFR IFNG TERT
43 11.64 ABCB1 TERT VEGFA
44
Show member pathways
11.63 IFNG TNF VEGFA
45 11.62 EGFR MDM2 TP53 VEGFA
46 11.58 BCL2 IFNG IL3 MDM2 TP53
47 11.54 MDM2 TP53 VEGFA
48 11.47 EGFR TNF VEGFA
49 11.47 EGFR IFNG TNF
50 11.44 BCL2 MDM2 TP53

GO Terms for Soft Tissue Sarcoma

Biological processes related to Soft Tissue Sarcoma according to GeneCards Suite gene sharing:

(show all 36)
id Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.96 BCL2 EGFR MKI67 TP53
2 positive regulation of apoptotic process GO:0043065 9.94 IFNG LATS1 TNF TP53
3 response to drug GO:0042493 9.92 ABCB1 BCL2 IFNG MDM2
4 positive regulation of gene expression GO:0010628 9.88 IFNG MDM2 TNF TP53 VEGFA
5 negative regulation of gene expression GO:0010629 9.86 IFNG MDM2 TERT TNF
6 positive regulation of protein phosphorylation GO:0001934 9.83 EGFR IFNG TNF VEGFA
7 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.77 IL3 TP53 VEGFA
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.76 IFNG IL3 VEGFA
9 positive regulation of MAP kinase activity GO:0043406 9.75 EGFR TNF VEGFA
10 humoral immune response GO:0006959 9.74 BCL2 IFNG TNF
11 positive regulation of cell proliferation GO:0008284 9.73 BCL2 EGFR IFNG IL3 MDM2 VEGFA
12 positive regulation of cell adhesion GO:0045785 9.72 IFNG TNF VEGFA
13 positive regulation of nitric oxide biosynthetic process GO:0045429 9.71 EGFR IFNG TNF
14 positive regulation of pri-miRNA transcription from RNA polymerase II promoter GO:1902895 9.67 TERT TP53
15 positive regulation of osteoclast differentiation GO:0045672 9.67 IFNG TNF
16 response to iron ion GO:0010039 9.66 BCL2 MDM2
17 positive regulation of protein export from nucleus GO:0046827 9.66 MDM2 TP53
18 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.65 IFNG TNF
19 negative regulation of growth of symbiont in host GO:0044130 9.64 IFNG TNF
20 digestive tract morphogenesis GO:0048546 9.63 BCL2 EGFR
21 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.63 MDM2 TERT
22 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.63 BCL2 TERT TNF
23 negative regulation of apoptotic process GO:0043066 9.63 BCL2 EGFR MDM2 TERT TP53 VEGFA
24 growth GO:0040007 9.62 BCL2 VEGFA
25 replicative senescence GO:0090399 9.61 TERT TP53
26 regulation of mitochondrial membrane permeability GO:0046902 9.61 BCL2 TP53
27 negative regulation of mitotic cell cycle GO:0045930 9.61 BCL2 EGFR TNF
28 positive regulation of chemokine biosynthetic process GO:0045080 9.59 IFNG TNF
29 positive regulation of protein complex assembly GO:0031334 9.54 IFNG TNF VEGFA
30 cellular response to actinomycin D GO:0072717 9.51 MDM2 TP53
31 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.5 MDM2 TERT TNF
32 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.49 IFNG TNF
33 positive regulation of vitamin D biosynthetic process GO:0060557 9.4 IFNG TNF
34 cellular response to hypoxia GO:0071456 9.35 BCL2 MDM2 TERT TP53 VEGFA
35 positive regulation of peptidyl-serine phosphorylation GO:0033138 8.92 BCL2 LATS1 TNF VEGFA
36 negative regulation of transcription from RNA polymerase II promoter GO:0000122 10.05 IFNG MDM2 TNF TP53 VEGFA

Molecular functions related to Soft Tissue Sarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 ubiquitin protein ligase binding GO:0031625 9.56 BCL2 EGFR MDM2 TP53
2 protease binding GO:0002020 9.5 BCL2 TNF TP53
3 protein N-terminus binding GO:0047485 9.37 MDM2 TP53
4 protein phosphatase binding GO:0019903 9.33 BCL2 EGFR TP53
5 cytokine activity GO:0005125 9.26 IFNG IL3 TNF VEGFA
6 identical protein binding GO:0042802 9.17 BCL2 EGFR EWSR1 MDM2 TNF TP53

Sources for Soft Tissue Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....